DOCSLIB.ORG

SAIZEN® Somatropin (Rmc), Recombinant Human Growth Hormone Consumer Medicine Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SAIZEN® Somatropin (Rmc), Recombinant Human Growth Hormone Consumer Medicine Information SAIZEN® Somatropin (rmc), recombinant human growth hormone Consumer Medicine Information What is in this leaflet SAIZEN contains somatropin, which You have diabetic retinopathy, an is the same as natural human growth eye disease caused by This leaflet answers some common hormone, but is made in a laboratory. complications of diabetes. questions about SAIZEN. If you are unsure as to why you You have an acute, critical It does not contain all of the available have been prescribed SAIZEN, ask illness, e.g. following major information. your doctor. surgery, or hospitalisation for an Your doctor may have prescribed it accident, or severe breathing It does not take the place of talking to disorders. your doctor, nurse or pharmacist. for another reason. SAIZEN should not be used for All medicines have benefits and SAIZEN is available only on a doctor's prescription. growth promotion in children if their risks. Your doctor has weighed the bones have stopped growing. risks of using SAIZEN against the benefits it is expected to have for In children with CRI, treatment with you. Saizen must be discontinued at the Before you use time of renal transplantation. If you have any concerns about using this medicine, ask your SAIZEN Do not use SAIZEN after the doctor, nurse or pharmacist. expiry date printed on the pack or When you must not use it if the packaging is torn or shows Keep this information with the signs of tampering. medicine. Do not use SAIZEN if you have an allergy to: If it has expired or is damaged, return You may need to read it again later. it to your pharmacist for disposal. somatropin If you are not sure whether you any of the other ingredients listed should start using this medicine, at the end of this leaflet. What SAIZEN is used talk to your doctor. for Some of the symptoms of an allergic reaction may include: Before you start to use it SAIZEN is used to treat: shortness of breath Tell your doctor if you have or Growth failure in children who wheezing or difficulty breathing have had any of the following medical conditions: have a deficiency of natural swelling of the face, lips, tongue human growth hormone. or other parts of the body Any type of cancer Growth failure in girls who have rash, itching or hives on the skin. Diabetes mellitus a genetic condition called gonadal Do not use SAIZEN if: Somatropin may cause blood dysgenesis, often referred to as sugar levels to increase. If you Turner Syndrome, which may You currently have any type of active cancer. are diabetic, your doctor will cause short stature. monitor your treatment and may Growth hormone deficiency in All cancer treatments must be change your treatment for adults. finished before starting treatment diabetes. with SAIZEN. Growth disturbance (growth Thyroid disorders You have an active brain lesion, retardation) in pre-pubertal Your doctor may prescribe children with chronic renal e.g. brain injury, abscess or tumour. another hormone to take if you insufficiency (CRI). are found to have developed a lack of thyroid hormone. SAIZEN® 1 If you have not told your doctor skin) injection, preferably in the Brain disorders about any of the above, tell evening. him/her before you start using Your doctor, nurse or pharmacist will If you have other hormone SAIZEN. deficiencies due to a previous instruct and assist you in learning the brain condition, your doctor techniques for preparing the needs to correct these before medicine and for self-injection. starting treatment with SAIZEN. Taking other medicines If your doctor has prescribed During treatment with SAIZEN, Tell your doctor if you are taking SAIZEN solution for injection, the your doctor will make regular any other medicines, including: medicine is provided in a cartridge with a dedicated autoinjector device examinations to check that your All prescription medicines (provided separately). The original brain disorder has not including any hormone autoinjector device provided with returned. replacement (e.g. oral oestrogen) your medicine can either be Your SAIZEN treatment may All medicines, vitamins, herbal electronic or hand-operated. need to be stopped if your brain supplements or natural therapies Follow the Instructions for Use condition returns. that you buy without a provided with the device carefully. Scoliosis prescription from your pharmacy, supermarket, naturopath or health Do not attempt self-injection until Your doctor needs to monitor for food shop. you are sure of how to do it. any signs of scoliosis as rapid growth in any child can cause Tell your doctor if you are taking Do not inject SAIZEN if it contains progression of scoliosis. corticosteroids. particles and is not clear. Corticosteroids are used to treat Liver or Kidney disorders Where to inject several illnesses including asthma, Your doctor may need to adjust allergies and rheumatoid arthritis. The best areas for injection are loose your SAIZEN treatment if you Corticosteroids might stop SAIZEN and soft (flabby) skin away from have any pre-existing condition from working well. joints and nerves. with your liver or kidney. If you are not sure if you are Use a different injection site each Treatment with SAIZEN in children taking any of these medicines, ask time to lessen the risk of damage to with CRI should only be started after your doctor or pharmacist. the fat and tissues under the skin. growth disturbance has been confirmed over a period of one year Your doctor and pharmacist have Prepare the injection site or upon your doctors discretion (for more information on medicines to be according to the instructions given example not less than 6 months in careful with or to avoid while using by your doctor, nurse or older children). SAIZEN. pharmacist. Children with CRI should be Suitable injection sites are: examined and monitored regularly Outside of the upper arm for evidence of bone disease. It is Abdomen (stomach) uncertain whether the bone disease How to use SAIZEN and its complications are affected by Upper outer buttocks SAIZEN therapy should be carried growth hormone therapy. Assessment Outside of the thigh. of the hip should be obtained prior to out under the regular guidance of a doctor who is experienced in the Do not inject into any areas in initiating therapy and at regular which you feel lumps, firm knots, intervals upon discretion of your diagnosis and management of growth depressions or pain. Talk to your doctor. hormone disorders. doctor, nurse or pharmacist if you Follow all directions given to you Tell your doctor if you are experience anything unusual when by your doctor, nurse or pregnant or breastfeeding, or plan injecting. pharmacist carefully. to become pregnant or start breastfeeding. They may differ from the How much to inject information contained in this leaflet. Your doctor will discuss with you the Your doctor will determine your dose risks and benefits of using SAIZEN How to inject and how frequently you inject (3, 6 if you are pregnant or breastfeeding. or 7 times a week). This depends on Also tell your doctor if you have SAIZEN is intended for you to inject why you are being treated with allergies to any other medicines, yourself by subcutaneous (under the SAIZEN, and your body surface area foods, preservatives, or dyes. or body weight. SAIZEN® 2 If you forget to inject it Do not stop using SAIZEN without Tell your doctor immediately if telling your doctor. you notice any of the following: If you forget a treatment, contact your doctor, nurse or pharmacist Do not change the dose unless your Symptoms of an allergic reaction for advice. doctor tells you to. which may include: Do not take a double dose to make shortness of breath up for the dose that you missed. wheezing or difficulty If you have trouble remembering Side effects breathing your injection schedule, ask your swelling of the face, lips, pharmacist or nurse for some tips. Tell your doctor as soon as possible tongue or other parts of the if you do not feel well while using body If you inject too much SAIZEN. rash, itching or hives on the Immediately contact your doctor SAIZEN helps most people needing skin. or the Poisons Information Centre treatment with growth hormone but it Unexplained limp or hip/knee (telephone 131 126 in Australia or may have unwanted side effects in pain. 0800 764 755 in New Zealand) if some people. All medicines can Strong or recurrent headache you are concerned that you or have side effects. Sometimes they associated with nausea, vomiting anyone else may have used too are serious, most of the time they are or sight disturbances. much SAIZEN. not. You may need medical Tell your doctor if you notice If you feel shaky or lightheaded, treatment if you get some side anything else that is making you contact your doctor immediately. effects. feel unwell. Injecting too much SAIZEN can lead Tell your doctor if you experience Other side effects not listed above to changes in blood sugar levels. any of the following side effects and they worry you: may also occur in some patients. Some side effects may only be found Pain, numbness, redness or when your doctor does tests from swelling at the injection site. time to time to check your progress. While you are using Muscle or joint pain or swelling, Do not be alarmed by this list of SAIZEN stiffness or pins and needles. possible side effects. Headache Things you must do You may not experience any of them. These side effects are more common Keep all of your doctor's in adult patients. They often appear appointments so that your progress at the start of treatment and are can be monitored.
Load more

Recommended publications
  • Saizen Prior Authorization Request Form (Page 1 of 4) DO NOT COPY for FUTURE USE
    OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations. Visit go.covermymeds.com/OptumRx to begin using this free service. Please note: All information below is required to process this request. Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific ® Saizen Prior Authorization Request Form (Page 1 of 4) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED Member Information (required) Provider Information (required) Member Name: Provider Name: Insurance ID#: NPI#: Specialty: Date of Birth: Office Phone: Street Address: Office Fax: City: State: Zip: Office Street Address: Phone: City: State: Zip: Medication Information (required) Medication Name: Strength: Dosage Form: Check if requesting brand Directions for Use: Check if request is for continuation of therapy Clinical Information (required) Select the diagnosis below: Pediatric growth hormone deficiency Growth hormone deficiency in adults Growth hormone deficiency in transition phase adolescents Isolated growth hormone deficiency in adults Pediatric growth failure associated with chronic renal insufficiency Prader-Willi syndrome Short-stature homeobox (SHOX) gene deficiency Small for gestational age (SGA) Turner syndrome or Noonan syndrome Other diagnosis: _________________________________________ ICD-10 Code(s): ___________________________________ Clinical Information: Select if the requested medication is prescribed by or in consultation with one of the following
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • ANONYMOUS V MERCK SERONO Conduct of Representative
    CASE AUTH/2591/3/13 ANONYMOUS v MERCK SERONO Conduct of representative An anonymous, non-contactable complainant, An anonymous, non-contactable complainant, complained about the conduct of an un-named complained about the conduct of an un-named representative from Merck Serono who had representative from Merck Serono. requested a monthly visit throughout 2013. The complainant stated that he/she felt harassed as COMPLAINT such frequent meetings were unnecessary. The complainant was informed that these visits were The complainant was concerned about a meeting required to meet an instruction to have meetings that he/she had had with a Merck Serono with seven health professionals each day. representative. The complainant alleged that the representative had requested that he/she plan a The complainant noted that before this episode, monthly visit with him/her throughout 2013. The he/she had always found the representative to be complainant stated that he/she felt harassed by this very professional and an asset to the company. The request as such frequent meetings were completely complainant considered that the representatives unnecessary. When the complainant asked why the were being forced to behave in this way by representative wanted to plan so many meetings in unrealistic expectations from their managers. advance he/she was informed that these visits were required to meet an instruction to have meetings The detailed response from Merck Serono is given with seven health professionals each day. below. The complainant noted that before this episode, he/ The Panel noted that Merck Serono’s instructions to she had always found this representative to be very its representatives referred to a number of different professional and an asset to his/her company.
    [Show full text]
  • GROWTH HORMONE (Adult Therapy) Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Sogroya*, Zomacton
    GROWTH HORMONE (Adult therapy) Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Sogroya*, Zomacton Bolded medications are the preferred products *This medication is included in this policy but is not available in the market as of yet RATIONALE FOR INCLUSION IN PA PROGRAM Background Growth hormone deficiency (GHD) in adulthood, associated with hypothalamic-pituitary dysfunction is now widely accepted as a distinct clinical syndrome, and is linked to a substantial number of significant co-morbidities, many of which can be ameliorated with growth hormone replacement therapy (1). The FDA has approved growth hormone replacement for use in adult patients with growth hormone deficiency. Approved indications are for the treatment of adults with either adult onset or childhood onset GHD. With the exception of idiopathic adult onset GHD, GHD should be confirmed as due to pituitary disease from known causes, including pituitary tumor, pituitary surgical damage, hypothalamic disease, irradiation, trauma, or reconfirmed childhood GHD. Growth hormone should only be prescribed to patients with clinical features suggestive of adult GHD and biochemically proven evidence of adult GHD (1-9). Regulatory Status FDA approved indications: Human growth hormone is indicated for treatment of adult patients with either childhood-onset or adult-onset GH deficiency (2-9). The laboratory diagnosis of GHD in adults is determined by dynamic endocrine testing. Because growth hormone has a short half-life in blood growth hormone levels frequently are undetectable in blood samples obtained at random from normal subjects. For this reason, a stimulation test is needed to confirm the diagnosis. American Association of Clinical Endocrinologists (AACE) does not recommend growth hormone stimulation testing in patients with three or more pituitary hormone deficiencies and low IGF1 (2-9).
    [Show full text]
  • Specialty Guideline Management
    Reference number(s) 1741-A SPECIALTY GUIDELINE MANAGEMENT GENOTROPIN (somatropin) HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) ZOMACTON (somatropin) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no contraindications or exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Pediatric patients with growth failure due to any of the following: a. Growth hormone (GH) deficiency b. Turner syndrome c. Noonan syndrome d. Small for gestational age (SGA) e. Prader-Willi syndrome f. Chronic kidney disease (CKD) g. Short stature homeobox-containing gene (SHOX) deficiency h. Idiopathic short stature (ISS)* 2. Adults with childhood-onset or adult-onset GH deficiency * ISS may not be covered by some plans B. Compendial Uses 1. Human immunodeficiency virus (HIV)-associated wasting/cachexia 2. Short bowel syndrome (SBS) 3. Growth failure associated with any of the following: a. Cerebral palsy b. Congenital adrenal hyperplasia c. Cystic fibrosis d. Russell-Silver syndrome All other indications are considered experimental/investigational and not medically necessary. II. REQUIRED DOCUMENTATION The following information is necessary to initiate the prior authorization review for both initial and continuation of therapy requests (where applicable): A. Medical records supporting the diagnosis of neonatal GH deficiency Growth Hormone With ISS 1741-A SGM P2021.docx © 2021 CVS Caremark. All rights reserved. This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.
    [Show full text]
  • Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020
    Medicines/pharmaceuticals of animal origin V3.0 November 2020 Medicines/pharmaceuticals of animal origin - This guideline provides information for all clinical staff within Hospital and Health Services (HHS) on best practice for avoidance of issues related to animal products. Medicines/pharmaceuticals of animal origin - V3.0 November 2020 Published by the State of Queensland (Queensland Health), November 2020 This document is licensed under a Creative Commons Attribution 3.0 Australia licence. To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au © State of Queensland (Queensland Health) 2020 You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health). For more information contact: Medication Services Queensland, Queensland Health, GPO Box 48, Brisbane QLD 4001, email [email protected] An electronic version of this document is available at https://www.health.qld.gov.au/__data/assets/pdf_file/0024/147507/qh-gdl-954.pdf Disclaimer: The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate
    [Show full text]
  • Saizen Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION ___________ WARNINGS AND PRECAUTIONS ___________ These highlights do not include all the information needed to use • Acute Critical Illness: Potential benefit of treatment continuation SAIZEN® safely and effectively. See full prescribing information should be weighed against the potential risk (5.1) for SAIZEN. • Prader-Willi syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of SAIZEN (somatropin) for injection, for subcutaneous use treatment. Discontinue treatment if these signs occur (5.2) Initial U.S. Approval: 1987 • Neoplasms: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm ______________ ______________ in childhood cancer survivors treated with somatropin—in INDICATIONS AND USAGE particular meningiomas as in patients treated with radiation to SAIZEN is a recombinant human growth hormone indicated for: the head for their first neoplasm (5.3) Pediatric: Treatment of children with growth failure due to growth • Impaired Glucose Tolerance and Diabetes Mellitus: May be hormone deficiency (GHD) (1.1) unmasked. Periodically monitor glucose levels in all patients Adult: Treatment of adults with either adult onset or childhood onset Doses of concurrent antihyperglycemic drugs in diabetics may GHD. (1.2) require adjustment (5.4) • Intracranial Hypertension: Exclude preexisting papilledema. ___________ DOSAGE AND ADMINISTRATION ___________ May develop and is usually reversible after discontinuation
    [Show full text]
  • Growth Hormones Is Recommended in Those Who Meet the Following Criteria
    Policy: 95015 Initial Effective Date: 06/22/1995 HCPCS J2170, J2940, J2941 and Q0515 Code(s): Annual Review Date: 06/17/2021 SUBJECT: Growth Stimulating Drugs Last Revised Date: 07/15/2021 - Genotropin(somatropin injection) - Humatrope (somatropin injection) - Increlex (mecasermin) - Norditropin® (somatropin injection) - Nutropin AQ (somatropin injection) - Omnitrope® (somatropin injection) - Saizen® (somatropin injection) - Serostim (somatropin injection) - Zomacton™ (somatropin injection) - Zorbtive (somatropin injection) - Sogroya(somapacitan injection) Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy. Definition: Exogenous growth hormone (recombinant human, rhGH) is a polypeptide hormone with metabolic effects similar to endogenous human growth hormone (GH). Produced in the pituitary gland, endogenous growth hormone activates production of insulin-like growth factor-1 (IGF-1) and other peptides that: modulate lipid, carbohydrate and protein metabolism; and stimulate development of bone, cartilage, skeletal muscle and gonadal tissue, leading to longitudinal growth. Inadequate secretion or impairment of growth hormone activity during childhood and adolescence may result in short stature, growth hormone deficiency with growth failure and other medical conditions. Exogenous growth hormone products approved by the U.S. Food and Drug Administration include somatropin (Humatrope®, Nutropin®, Serostim®, Saizen®, Norditropin®, Genotropin®, Zorbtive®, Omnitrope®, ZomactonTM). These products are
    [Show full text]
  • Saizen® [Somatropin (Rdna Origin) for Injection] for Subcutaneous Or Intramuscular Injection
    Saizen® [somatropin (rDNA origin) for injection] For subcutaneous or intramuscular injection DESCRIPTION Saizen® [somatropin (rDNA origin) for injection] is a human growth hormone produced by recombinant DNA technology. Saizen® has 191 amino acid residues and a molecular weight of 22,125 daltons. Its amino acid sequence and structure are identical to the dominant form of human pituitary growth hormone. Saizen® is produced by a mammalian cell line (mouse C127) that has been modified by the addition of the human growth hormone gene. Saizen®, with the correct three-dimensional configuration, is secreted directly through the cell membrane into the cell-culture medium for collection and purification. Saizen® is a highly purified preparation. Biological potency is determined by measuring the increase in body weight induced in hypophysectomized rats. Saizen® is a sterile, non-pyrogenic, white, lyophilized powder intended for subcutaneous or intramuscular injection after reconstitution with Bacteriostatic Water for Injection, USP (0.9% Benzyl Alcohol). The reconstituted solution has a pH of 6.5 to 8.5. Saizen® is available in 5 mg and 8.8 mg vials. The quantitative composition per vial is: 5 mg (approximately 15 IU) vial: Each vial contains 5.0 mg somatropin (approximately 15 IU), 34.2 mg sucrose and 1.16 mg O-phosphoric acid. The pH is adjusted with sodium hydroxide or O- phosphoric acid. 8.8 mg (approximately 26.4 IU) vial: Each vial contains 8.8 mg somatropin (approximately 26.4 IU), 60.2 mg sucrose and 2.05 mg O-phosphoric acid. The pH is adjusted with sodium hydroxide or O- phosphoric acid.
    [Show full text]
  • SAIZEN® [Somatropin (Rdna Origin) for Injection], NDA 19-764/S-020 DRAFT PACKAGE INSERT: Adult Growth Hormone Deficiency (Submitted 10.26.04)
    SAIZEN® [somatropin (rDNA origin) for injection], NDA 19-764/S-020 DRAFT PACKAGE INSERT: Adult Growth Hormone Deficiency (Submitted 10.26.04) Saizen® [somatropin (rDNA origin) for injection] For subcutaneous or intramuscular injection DESCRIPTION Saizen® [somatropin (rDNA origin) for injection] is a human growth hormone produced by recombinant DNA technology. Saizen® has 191 amino acid residues and a molecular weight of 22,125 daltons. Its amino acid sequence and structure are identical to the dominant form of human pituitary growth hormone. Saizen® is produced by a mammalian cell line (mouse C127) that has been modified by the addition of the human growth hormone gene. Saizen®, with the correct three-dimensional configuration, is secreted directly through the cell membrane into the cell-culture medium for collection and purification. Saizen® is a highly purified preparation. Biological potency is determined by measuring the increase in body weight induced in hypophysectomized rats. Saizen® is a sterile, non-pyrogenic, white, lyophilized powder intended for subcutaneous or intramuscular injection after reconstitution with Bacteriostatic Water for Injection, USP (0.9% Benzyl Alcohol). The reconstituted solution has a pH of 6.5 to 8.5. Saizen® is available in 5 mg and 8.8 mg vials. The quantitative composition per vial is: 5 mg (approximately 15 IU) vial: Each vial contains 5.0 mg somatropin (approximately 15 IU), 34.2 mg sucrose and 1.16 mg O-phosphoric acid. The pH is adjusted with sodium hydroxide or O- phosphoric acid. 8.8 mg (approximately 26.4 IU) vial: Each vial contains 8.8 mg somatropin (approximately 26.4 IU), 60.2 mg sucrose and 2.05 mg O-phosphoric acid.
    [Show full text]
  • Formulary Drug List
    ABALOPARATIDE Products Affected • TYMLOS PA Criteria Criteria Details Exclusion PATIENT HAS RECEIVED A TOTAL OF 24 MONTHS Criteria CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY. Required Medical Information Age Restrictions Prescriber Restrictions Coverage 12 MONTHS Duration 1 PA Criteria Criteria Details Other Criteria ONE OF THE FOLLOWING: (1) HIGH RISK FOR FRACTURES DEFINED AS ONE OF THE FOLLOWING: (A) HISTORY OF OSTEOPOROTIC (I.E., FRAGILITY, LOW TRAUMA) FRACTURE(S), (B) 2 OR MORE RISK FACTORS FOR FRACTURE (E.G., HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS), OR (C) NO PRIOR TREATMENT FOR OSTEOPOROSIS AND FRAX SCORE OF AT LEAST 20% FOR ANY MAJOR FRACTURE OR OF AT LEAST 3% FOR HIP FRACTURE. (2) UNABLE TO USE ORAL THERAPY (I.E., UPPER GASTROINTESTINAL PROBLEMS UNABLE TO TOLERATE ORAL MEDICATION, LOWER GASTROINTESTINAL PROBLEMS UNABLE TO ABSORB ORAL MEDICATIONS, TROUBLE REMEMBERING TO TAKE ORAL MEDICATIONS OR COORDINATING AN ORAL BISPHOSPHONATE WITH OTHER ORAL MEDICATIONS OR THEIR DAILY ROUTINE). (3) ADEQUATE TRIAL OF, INTOLERANCE TO, OR A CONTRAINDICATION TO ONE BISPHOSPHONATE. Indications All FDA-approved Indications. Off Label Uses 2 ABATACEPT IV Products Affected • ORENCIA (WITH MALTOSE) PA Criteria Criteria Details Exclusion Criteria Required Medical Information Age Restrictions Prescriber RHEUMATOID ARTHRITIS AND POLYARTICULAR Restrictions JUVENILE IDIOPATHIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. Coverage INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. Duration Other Criteria INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF OR CONTRAINDICATION TO ANY TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ, RINVOQ.
    [Show full text]
  • References (PDF)
    References I-9012 1. Saizen prescribing information. EMD Serono, Inc. February 2020. 2. Serostim prescribing information. EMD Serono, Inc. June 2019. 3. Zorbtive prescribing information. EMD Serono, Inc. September 2019. 4. Genotropin prescribing information. Pfizer, Inc./Pharmacia and Upjohn Co. April 2019. 5. Humatrope prescribing information. Eli Lilly and Company. October 2019. 6. Norditropin FlexPro prescribing information. Novo Nordisk Inc. March 2020. 7. Omnitrope prescribing information. Sandoz Inc. June 2019. 8. Nutropin AQ NuSpin prescribing information. December 2016. 9. Zomacton prescribing information. Ferring Pharmaceuticals Inc. July 2018. 10. Richmond EJ, Rogol AD, et al. Diagnosis of Growth Hormone Deficiency in Children. UptoDate. Literature review current through June 2020. Last updated March 2020. Accessed July 2020. 11. Grimberg A, DiVall SA, Polychronakos C, et al. Pediatric Endocrine Society Guidelines for Growth Hormone and Insulin-Like Growth Factor-1 Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-1 Deficiency. Horm Res Paediatr. 2016;86:361–397. 12. Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Growth Hormone Research Society International Perspective Guidelines for Diagnosis, Genetics, and Therapy of Short Stature in Children. Horm Res Paediatr. 2019;92:1-14. 13. Growth Hormone Research Society (GRS) Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement. J Clin Endocrinol Metab. 2000;85(11):3990-3993. 14. Richmond EJ, Rogol AD, et al. Diagnostic Approach to Children and Adolescents with Short Stature. UptoDate. Literature review current through June 2020. Last updated January 2020. Accessed July 2020.
    [Show full text]